Saline syringe

The mixed solution obtained was then placed in a syringe and allowed to drop into a sterile 0.2M CaCli solution that was stirred continuously. Alginate drops solidified upon contact with CaCh, forming beads and thus entrapping bacteria cells. The beads were allowed to harden for 30 minutes at 37 C and then washed with sterile saline solution to remove excess calcium ions and untrapped cells. 

In contrast, parenteral suspensions have relatively low solids contents, usually between 0.5 and 5%, with the exception of insoluble forms of penicillin in which concentrations of the antibiotic may exceed 30%. These sterile preparations are designed for intramuscular, intradermal, intralesional, intraarticular, or subcutaneous injection. Syringeability is an important factor to be taken into consideration with injectable dosage forms. The viscosity of a parenteral suspension should be sufficiently low to facilitate injection. Common suspending vehicles include preserved isotonic saline solution or a parenterally acceptable vegetable oil. Ophthalmic and optic suspensions that are instilled into the eye/ear must also be prepared in a sterile manner. The vehicles are essentially isotonic and aqueous in composition. The reader should refer to Chapter 12 for further discussion on parenteral products. 

If the capsule cannot be swallowed (eg, time of surgery, unconscious patient), make a hole in both ends of the capsule with an 18 gauge needle and extract the contents into a syringe. Empty the contents into the patient s in situ nasogastric tube and wash down the tube with 30 mg normal saline. 

The short lived positron-emitter Rb-82 (t 1/2=1.26m) has potential application in cardiovascular diagnostic nuclear medicine. A generator system containing the parent Sr-82 has been developed that will provide an eluate of Rb-82 suitable for direct infusion. The Rb-82 is eluted by a syringe pump from a hydrous stannic oxide column in a continuous stream of physiological saline solution. The rate of elution (infusion) can be controlled from 10 to 100 ml/ min. At elution rates of 25, 50, and 75 ml/min,... 

Open the bottom tap, and gently draw into the syringe as much of the saline as possible. Close the tap, remove the syringe, and discard the saline aseptically If necessary, replace the syringe, and repeat this procedure until the bioreactor is as empty as possible. 

Dilute insulin in saline to the desired concentration 1-5 U/10 ml. Keep on ice during preparation. Mix gently and preload syringes. 

Blood is collected in a heparinised syringe and the red cells washed three times in 0.85% saline by sedimentation at 200g for 10 min and resuspension. They are finally resuspended in 200 volumes 0.85% saline. 

Sodium hyaluronate appears to be free of adverse ocular or systemic effects when nsed topically on the eye at the 0.1% concentration. Cnrrent limitations to its use as an artificial tear are the absence of a commercial preparation for the dry eye and its cost this agent is considerably more expensive than other dry eye preparations for longterm use. It is available in disposable syringes and can be prepared as a 0.1% topical solntion in saline. 

Edrophonium is available in multiple-dose or singledose 10-mg/ml ampules. An accessible vein is foimd on one of the patient s arms, and a butterfly infusion set with a 27-gauge needle is attached to a 1-ml tuberculin syringe containing 10 mg edrophonium solution. Initially, 2 mg (0.2 ml) edrophonium is injected intravenously. A saline flush may follow this injection to confirm appropriate dose administration. If after 1 or 2 minutes definite improvement in ptosis or ocular misalignment occurs, the test is considered positive and no further edrophonium injection is necessary. If no definite improvement occurs, however, another 3 mg (0.3 ml) edrophonium is injected and the patient is again observed. 

The diluent of sterile normal saline is drawn up in a syringe and gently injected into the vial containing the Botox. Rapid forceful injection that causes frothing or other mechanical stress is discouraged because this can inactivate the toxin. Table 22-7 gives the recommended dilutions calculated for an injection volume of 0.1 ml. 

The syringe of the lacrimal irrigation apparatus is filled with sterile saline. 

The clinician then attempts to inject a small amount (1 to 2 ml) of saline into the punctum by depressing the plunger on the syringe. 

A syringe is prepared with heparinized saline and a 21-, 23-, or 25-gauge scalp-vein needle, and the patient is phlebotomized, usually in the antecubital vein. Fluorescein may also be injected into the veins of the back of the hand or wrist. The needle must be monitored, because extravasation of dye results in localized pain. Before injecting fluorescein the photographer takes baseline color photographs and then red-free fundus pictures. 

Adrenaline acid tartrate (0.4mg/L in normal saline and packaged in polypropylene syringes) exposed for 24 hours to ambient illuminating conditions also showed no loss of potency (78). However, various epinephrine preparations may vary in their stability, depending on the form of epinephrine as well as the preservatives and packaging used. Hoechst (today, Sanofi-Aventis) claims that, according to their experimental studies, diluted solutions (0.2,1,2mg/L) of Arterenol (norepinephrine HCL) and Suprarenin (epinephrine HCL) are stable for up to 24 hours in polypropylene syringes, if stored without photoprotection. 

Dissolve the immunogen in isotonic saline (other immunogens may require slight acidity, alkalinity, or other special condition) to a volume of 0.5 ml per rabbit for the primary injection or 0.25 ml for boosters (i.e., the same concentration for both injections). Emulsify the solution with three volumes of Freund s complete adjuvant, using a double-hub connector and two syringes as described above. The total volume of emulsion will then be 2 ml per rabbit for the primary inoculation or 1 ml for a booster. Use the emulsion within an hour of preparation. 

Small doses of heparin are used for the prophylaxis of infusion-related thrombophlebitis (23). Low molecular weight heparin is added to recombinant factor Vila to prevent a 50% loss of activity of factor VII within 4 hours of storage (9). In one case, however, there was co-preci-pitation of reconstituted factor Vila and low molecular weight heparin in syringes (24). The authors therefore suggested that a parallel saline infusion be used instead of heparin to prevent thrombophlebitis. 

---